INMUNE BIO ($INMB) posted quarterly earnings results for Q1 2026 on Thursday, May 7th. The company reported earnings of -$0.20 per share, beating estimates of -$0.21 by $0.01. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $INMB stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
INMUNE BIO Hedge Fund Activity
We have seen 38 institutional investors add shares of INMUNE BIO stock to their portfolio, and 31 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DAUNTLESS INVESTMENT GROUP, LLC added 304,922 shares (+inf%) to their portfolio in Q4 2025, for an estimated $475,678
- UBS GROUP AG added 192,537 shares (+316.7%) to their portfolio in Q1 2026, for an estimated $217,566
- ACT CAPITAL MANAGEMENT, LLC removed 151,100 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $235,716
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 93,956 shares (+59.9%) to their portfolio in Q4 2025, for an estimated $146,571
- VANGUARD GROUP INC added 81,554 shares (+9.3%) to their portfolio in Q4 2025, for an estimated $127,224
- STATE STREET CORP added 63,426 shares (+22.3%) to their portfolio in Q4 2025, for an estimated $98,944
- RAYMOND JAMES FINANCIAL INC removed 57,782 shares (-21.5%) from their portfolio in Q4 2025, for an estimated $90,139
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
